• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Under Affordable Care Act, Americans have had more preventive care for heart health, UCLA study finds
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health,a UCLA study found. Comparing figures from 2006 through 2013, researchers found that more people were screened for diabetes, high cholesterol, cigarette use and high blood pressure — all risk factors for heart disease — after the ACA was implemented than before.But the research, published in the peer-reviewed American Journal of Managed Care, also revealed a disparity between men and women in one key area. Although more men who are at r...
Source: UCLA Newsroom: Health Sciences - November 23, 2017 Category: Universities & Medical Training Source Type: news

10 Good Reasons To Get A Flu Shot
By Melaina Juntti for Men's Journal How many times have you heard you should get a flu shot? There's good reason for the hype: Over the past few years, the influenza vaccine has prevented millions of flu cases and tens of thousands of related hospitalizations, according to Centers for Disease Control and Prevention. Although an increasing number of people are getting vaccinated every year, more than half of American men still aren't doing it, for a variety of reasons, most of which aren't backed by science. "Men have this macho sense that if they do get the flu, they can tough it out," says William Schaffner, M.D., chair...
Source: Science - The Huffington Post - November 29, 2014 Category: Science Source Type: news

In Times of Uncertainty, Keep Calm and Get Covered
It's no secret that the Affordable Care Act, President Obama's signature healthcare legislation, is facing an uncertain future. The incoming administration has pledged to repeal the law and offer an alternative in its place. But this uncertain future should not keep you from taking advantage of what is available to you and your loved ones today. Thursday is the deadline to ensure coverage under the ACA when the calendar turns to 2017. This goes for both uninsured Americans seeking coverage and those who need to re-enroll. Missing the deadline doesn't mean you're out; it just means you won't have coverage Jan. 1. The final...
Source: Healthy Living - The Huffington Post - December 13, 2016 Category: Consumer Health News Source Type: news

How to Keep Alzheimer ’s From Bringing About the Zombie Apocalypse
I tried to kill my father for years. To be fair, I was following his wishes. He’d made it clear that when he no longer recognized me, when he could no longer talk, when the nurses started treating him like a toddler, he didn’t want to live any longer. My father was 58 years old when he was diagnosed with Alzheimer’s disease. He took the diagnosis with the self-deprecating humor he’d spent a lifetime cultivating, constantly cracking jokes about how he would one day turn into a zombie, a walking corpse. We had a good 10 years with him after the diagnosis. Eventually, his jokes came true. Seven years ...
Source: TIME: Health - November 20, 2019 Category: Consumer Health News Authors: Jay Newton-Small Tags: Uncategorized Alzheimer's Disease Source Type: news

Rural U.S. Hospitals Are On Life Support As a Third Wave of COVID-19 Strikes
When COVID-19 hit the Southwest Georgia Regional Medical Center in Cuthbert, a small rural town in Randolph County, in late March, the facility—which includes a 25-bed hospital, an adjacent nursing home and a family-medicine clinic, was quickly overwhelmed. In just a matter of days, 45 of the 62 nursing home residents tested positive. Negative residents were isolated in the hospital while the severely ill patients from both the nursing home and the local community were transferred to other better-equipped facilities. “We were trying to get the patients out as fast as possible,” says Steve Whatley, Southwe...
Source: TIME: Health - October 20, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Decreasing rates of cost-related medication non-adherence by age advancement among American generational cohorts 2004-2014: a longitudinal study
Conclusion The paradox of decreasing CRN rates, independent of disease burden, income and insurance status, suggests populations’ CRN behaviours change as Americans age, bearing implications to social policy.
Source: BMJ Open - May 6, 2022 Category: General Medicine Authors: Zhang, J., Bhaumik, D., Meltzer, D. Tags: Open access, Health economics Source Type: research